Dr William Oh, an expert in the management of genitourinary malignancies, including prostate, renal, bladder, and testicular cancers, recently joined the Mount Sinai School of Medicine as director of the Division of Hematology and Medical Oncology, co-director of the Prostate Cancer Program, and associate director for clinical research for The Tisch Cancer Institute. Dr Oh's research interests include the role of chemotherapy and novel therapeutics in advanced prostate cancer. A leading investigator in the use of neoadjuvant chemotherapy in men with high-risk localized prostate cancer, he has served as the principal investigator of multiple clinical trials in prostate and other GU cancers. In addition, he developed a large clinical database and specimen repository for GU cancers which has enrolled over 6000 patients with prostate, renal and bladder cancer in the past decade. Dr Oh has authored more 150 original articles, reviews, and book chapters on topics relating to prostate, renal, bladder, and testicular cancers. He has recently edited two books on prostate cancer. He has served on the Cancer Education Committee of the American Society of Clinical Oncology (ASCO) and is a core member of the Genitourinary Committee of Cancer and Leukemia Group B (CALGB). In addition to reviewing for prominent journals such as the New England Journal of Medicine, Journal of Clinical Oncology, and Cancer, Dr Oh co-edits “Testicular Cancer” for UpToDate and is on the editorial boards of Clinical Genitourinary Cancer and American Journal of Hematology and Oncology. Dr Oh received his MD from New York University School of Medicine. He completed his internship and residency in internal medicine at Brigham and Womens Hospital in Boston. Dr Oh subsequently completed a fellowship in medical oncology at the Dana-Farber Cancer Institute in 1997. Prior to joining the Mount Sinai School of Medicine, Dr Oh has served as clinical director of the Lank Center for Genitourinary Oncology and directed the Gelb Center for Translational Research at the Dana-Farber Cancer Institute and Harvard Medical School in Boston, Massachusetts. As clinical director of the Lank Center, Dr Oh oversaw a team of clinical and laboratory-based medical oncologists and nurse practitioners, and directed a multidisciplinary GU clinic that included radiation oncologists and urologists. He served as the founding chair of the Data and Safety Monitoring Committee for Phase I/II Trials at the Dana-Farber/Harvard Cancer Center. He has regularly taught physicians, nurses, medical students and pharmacists through ground rounds, tumor boards, and lectures at Harvard Medical School and elsewhere.